Zentalis Pharmaceuticals (NASDAQ:ZNTL) Upgraded by Wedbush to “Neutral”

Wedbush upgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) from an underperform rating to a neutral rating in a report published on Monday, MarketBeat Ratings reports. Wedbush currently has $4.00 price objective on the stock. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q3 2024 earnings at ($0.86) EPS, Q4 2024 earnings at ($0.87) EPS, FY2024 earnings at ($2.83) EPS, Q1 2025 earnings at ($0.91) EPS, Q2 2025 earnings at ($0.92) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.74) EPS, FY2025 earnings at ($3.25) EPS, FY2026 earnings at ($2.89) EPS, FY2027 earnings at ($2.19) EPS and FY2028 earnings at ($1.31) EPS.

ZNTL has been the topic of a number of other reports. Wells Fargo & Company cut shares of Zentalis Pharmaceuticals from an overweight rating to an equal weight rating and reduced their price objective for the company from $29.00 to $9.00 in a research note on Tuesday, June 18th. Jefferies Financial Group reissued a hold rating and set a $6.00 price target (down from $42.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday, June 18th. Oppenheimer reduced their price target on shares of Zentalis Pharmaceuticals from $50.00 to $25.00 and set an outperform rating on the stock in a research report on Tuesday, June 18th. HC Wainwright reissued a buy rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Monday. Finally, Morgan Stanley reissued an equal weight rating and set a $8.00 price target (down from $38.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday, June 18th. Seven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, Zentalis Pharmaceuticals presently has a consensus rating of Hold and an average target price of $11.33.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock opened at $2.90 on Monday. Zentalis Pharmaceuticals has a 52-week low of $2.83 and a 52-week high of $28.47. The stock has a market cap of $205.62 million, a PE ratio of -0.87 and a beta of 1.70. The firm’s 50 day moving average price is $4.88 and its two-hundred day moving average price is $10.17.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Friday, August 9th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). During the same quarter in the previous year, the company earned ($1.85) EPS. As a group, sell-side analysts predict that Zentalis Pharmaceuticals will post -2.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Cam Gallagher sold 9,597 shares of the firm’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $11.98, for a total transaction of $114,972.06. Following the sale, the chief financial officer now directly owns 633,680 shares in the company, valued at $7,591,486.40. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Eventide Asset Management LLC increased its stake in Zentalis Pharmaceuticals by 47.9% in the 4th quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock valued at $175,134,000 after buying an additional 3,745,936 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Zentalis Pharmaceuticals by 20.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after buying an additional 585,644 shares during the last quarter. Federated Hermes Inc. increased its stake in Zentalis Pharmaceuticals by 10.9% in the 4th quarter. Federated Hermes Inc. now owns 2,160,565 shares of the company’s stock valued at $32,733,000 after buying an additional 212,872 shares during the last quarter. Decheng Capital LLC acquired a new stake in Zentalis Pharmaceuticals in the 4th quarter valued at $31,809,000. Finally, Primecap Management Co. CA increased its stake in Zentalis Pharmaceuticals by 5.8% in the 2nd quarter. Primecap Management Co. CA now owns 1,232,340 shares of the company’s stock valued at $5,040,000 after buying an additional 67,730 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.